Learning objectives of this session
There will be two late-breaking studies dealing with the treatment of non-muscle invasive bladder cancer (NMIBC): The EAU – RF sponsored prospective randomized multi-institutional study shedding light on the dose of BCG and its effect on clinical outcome. The other study is a phase III study showing a completely new concept of intravesical instillation in high-grade BCG-unresponsive NMIBC, which might change the approach to the management of NMIBC.

07:30 - 07:45
Recurrence Risk in patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ stratified for EORTC and CUETO risk categories. A contemporary trend to less recurrences?
*Speaker:* M-O. Grimm, Jena (DE)
*Discussant:* P. Black, Vancouver (CA)

07:45 - 08:00
Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients (pts) with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
*Speaker:* N. Shore, Myrtle Beach (US)
*Discussant:* J.A. Witjes, Nijmegen (NL)